story of the week
Risk of Acute Upper Respiratory Infections in Patients With Atopic Dermatitis Treated With Dupilumab vs Non-Targeted Immunosuppressants
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dupilumab is associated with reduced risk of acute upper respiratory infections in atopic dermatitis patients compared to non-targeted immunosuppressants: a multi-center cohort study
J Am Acad Dermatol 2024 Aug 30;[EPub Ahead of Print], EZ Ma, A Bao, M Ahmadi, J Zhang, SG KwatraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.